{"id":21019,"date":"2022-02-21T15:07:15","date_gmt":"2022-02-21T14:07:15","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=21019"},"modified":"2022-02-21T15:07:19","modified_gmt":"2022-02-21T14:07:19","slug":"amr-industry-alliance-progress-report-2021-member-survey","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/","title":{"rendered":"AMR Industry Alliance Progress Report, 2021 Member survey"},"content":{"rendered":"\n<p>Article published on <a href=\"https:\/\/www.amrindustryalliance.org\/progress-report\/\" target=\"_blank\" rel=\"noreferrer noopener\">AMR Industry Alliance<\/a><\/p>\n\n\n\n<p>The AMR Industry Alliance\u2019s Progress Report reflects on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR). Findings from the leading coalition of biotechnology, diagnostics, generic and large research-based pharmaceutical companies indicate continued focus and leadership from the life sciences sector. Industry is helping to shape a positive future outlook in the fight against AMR but continued cross-sector collaborations along with policy and regulatory changes toward a more sustainable marketplace are needed. The report\u2019s findings represent collective results from across Alliance membership on their current AMR activities related to research and science, access, appropriate use, and manufacturing and the environment.&nbsp; The report was conducted by RAND Europe.<\/p>\n\n\n\n<p>Key findings include:<\/p>\n\n\n\n<ul><li><strong>There is continued funding in AMR from Alliance members, but investment levels are at risk.<\/strong>\u00a0Since the previous survey period (2019-2020), at least USD$1.8 billion have been invested annually. Nearly one-third of members reported that investment would decrease if market conditions did not improve.<\/li><li><strong>Incentives for R&amp;D in antibiotics are critical for future investment.\u00a0<\/strong>Almost three-quarters of Alliance members said they would increase investment if market conditions improved, particularly through sufficient novel pull incentives. These reward successful development and will be imperative to ensure market viability and enable sustainable investment into AMR R&amp;D.<\/li><li><strong>An overwhelming majority of Alliance members are active in access and appropriate use activities.<\/strong>\u00a0Four out of five (81%) surveyed companies reported being active in supporting access to AMR-relevant products and\/or technologies. Implementation of appropriate use and stewardship activities were also reported as a major focus of companies, with 92% of R&amp;D pharmaceutical companies, 89% of generics companies, and 80% of diagnostics companies having taken such actions.<\/li><li><strong>There is growing commitment and action on responsible manufacturing.<\/strong>\u00a0An increasing number of Alliance members involved in manufacturing antibiotics (85%) are assessing their sites against the Alliance\u2019s\u00a0<a href=\"https:\/\/www.amrindustryalliance.org\/wp-content\/uploads\/2018\/02\/AMR_Industry_Alliance_Manufacturing_Framework.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Common Antibiotic Manufacturing Framework<\/a>\u00a0(CAMF), and 87% of products manufactured at Alliance members sites are meeting its science-based predicted no-effect concentrations (PNEC) targets.<\/li><\/ul>\n\n\n\n<p><em>The report is based on independent, quality assured research conducted by\u00a0<a href=\"https:\/\/www.rand.org\/randeurope.html\" target=\"_blank\" rel=\"noreferrer noopener\">RAND Europe<\/a>\u00a0and funded by the AMR Industry Alliance.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article published on AMR Industry Alliance The AMR Industry Alliance\u2019s Progress Report reflects on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR). Findings from the leading coalition of biotechnology, diagnostics, generic and large research-based pharmaceutical companies indicate continued focus and leadership from the life sciences sector. Industry is [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":21029,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AMR Industry Alliance Progress Report, 2021 Member survey - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AMR Industry Alliance Progress Report, 2021 Member survey - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-21T14:07:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-21T14:07:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"850\" \/>\n\t<meta property=\"og:image:height\" content=\"537\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"AMR Industry Alliance Progress Report, 2021 Member survey\",\"datePublished\":\"2022-02-21T14:07:15+00:00\",\"dateModified\":\"2022-02-21T14:07:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/\"},\"wordCount\":364,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/\",\"name\":\"AMR Industry Alliance Progress Report, 2021 Member survey - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg\",\"datePublished\":\"2022-02-21T14:07:15+00:00\",\"dateModified\":\"2022-02-21T14:07:19+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg\",\"width\":850,\"height\":537,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bilans, rapports et recommandations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"AMR Industry Alliance Progress Report, 2021 Member survey\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AMR Industry Alliance Progress Report, 2021 Member survey - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/","og_locale":"fr_FR","og_type":"article","og_title":"AMR Industry Alliance Progress Report, 2021 Member survey - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2022-02-21T14:07:15+00:00","article_modified_time":"2022-02-21T14:07:19+00:00","og_image":[{"width":850,"height":537,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"AMR Industry Alliance Progress Report, 2021 Member survey","datePublished":"2022-02-21T14:07:15+00:00","dateModified":"2022-02-21T14:07:19+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/"},"wordCount":364,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/","name":"AMR Industry Alliance Progress Report, 2021 Member survey - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg","datePublished":"2022-02-21T14:07:15+00:00","dateModified":"2022-02-21T14:07:19+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Courbe-progression.jpg","width":850,"height":537,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/amr-industry-alliance-progress-report-2021-member-survey\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Bilans, rapports et recommandations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/"},{"@type":"ListItem","position":4,"name":"AMR Industry Alliance Progress Report, 2021 Member survey"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-18 13:33:23","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/21019"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=21019"}],"version-history":[{"count":7,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/21019\/revisions"}],"predecessor-version":[{"id":21037,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/21019\/revisions\/21037"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/21029"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=21019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=21019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=21019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}